Nkarta, Inc. NKTX
Set alert
1.56 USD -0.10 -6.02%
At close · Oct 30
1.60 +0.04 +2.56%
After hours · Oct 30, 7:17 PM ET
1.54 Day range 1.66
1.56 52-week range 3.67
- YTD
- -15.68%
- 1 year
- -25.00%
- Open
- 1.66
- Prev close
- 1.66
- Mkt cap
- 111.73M
- Vol
- 1.21M
- Avg vol
- 732.10K
- EPS
- -1.58
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.54
- High
- 1.66
- Forward P/E
- -1.42
- Beta
- 0.87
- Short ratio
- 5.44
- Inst. own
- 99.79%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 13, 2024
- 50-d avg
- 3.03
- 200-d avg
- 5.86
- 1y target
- 15.83
2Y chart
Events in this range
- Nov 7, 2024Earnings: -0.39; estimate -0.37; surprise -5.41%
- Nov 8, 2024Rating: Needham · Buy → Buy
- Nov 11, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 21, 2024Rating: Mizuho · Outperform → Outperform
Signals (103)
| Name | Date | Ago |
|---|---|---|
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| SMA: Bearish | Oct 1, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 17, 2026 | 1 month ago |
| RSI: Overbought | Sep 8, 2026 | 1 month ago |
| SMA: Bullish | Aug 25, 2026 | 2 months ago |
| SMA: Bearish | Aug 24, 2026 | 2 months ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bullish | Aug 17, 2026 | 2 months ago |
| SMA: Bearish | Aug 11, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Jul 23, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 14, 2026 | 3 months ago |
| SMA: Bearish | Jul 13, 2026 | 3 months ago |
| RSI: Overbought | Jul 8, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| SMA: Bearish | Jun 24, 2026 | 4 months ago |
| SMA: Bullish | Jun 23, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 22, 2026 | 4 months ago |
| SMA: Bearish | Jun 15, 2026 | 4 months ago |
| SMA: Bullish | Jun 12, 2026 | 4 months ago |
| SMA: Bearish | Jun 3, 2026 | 5 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| MACD: Sell Signal | May 13, 2026 | 5 months ago |
| MACD: Buy Signal | May 6, 2026 | 5 months ago |
| MACD: Sell Signal | Apr 29, 2026 | 6 months ago |
| RSI: Overbought | Apr 17, 2026 | 6 months ago |
| SMA: Bullish | Apr 13, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 8, 2026 | 6 months ago |
| SMA: Bearish | Apr 7, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 6, 2026 | 6 months ago |
| SMA: Bullish | Apr 2, 2026 | 7 months ago |
| SMA: Bullish | Mar 31, 2026 | 7 months ago |
| SMA: Bearish | Mar 27, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 24, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 11, 2026 | 7 months ago |
| RSI: Overbought | Feb 26, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 19, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bullish | Feb 17, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bullish | Feb 6, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| SMA: Bearish | Feb 5, 2026 | 8 months ago |
| MACD: Sell Signal | Feb 2, 2026 | 9 months ago |
| RSI: Overbought | Jan 22, 2026 | 9 months ago |
| SMA: Bullish | Jan 16, 2026 | 9 months ago |
| SMA: Bearish | Jan 15, 2026 | 9 months ago |
| RSI: Overbought | Jan 12, 2026 | 9 months ago |
| RSI: Overbought | Jan 8, 2026 | 9 months ago |
| SMA: Bullish | Jan 7, 2026 | 9 months ago |
| SMA: Bullish | Jan 6, 2026 | 9 months ago |
| MACD: Buy Signal | Nov 28, 2025 | 11 months ago |
| SMA: Bearish | Nov 12, 2025 | 11 months ago |
| SMA: Bullish | Nov 11, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| SMA: Bearish | Oct 29, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 27, 2025 | 1 year ago |
| MACD: Buy Signal | Oct 24, 2025 | 1 year ago |
| MACD: Sell Signal | Oct 23, 2025 | 1 year ago |
| SMA: Bullish | Oct 9, 2025 | 1 year ago |
| SMA: Bearish | Oct 7, 2025 | 1 year ago |
| SMA: Bullish | Oct 1, 2025 | 1 year ago |
| SMA: Bullish | Sep 26, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 26, 2025 | 1 year ago |
| SMA: Bearish | Sep 25, 2025 | 1 year ago |
| SMA: Bullish | Sep 22, 2025 | 1 year ago |
| SMA: Bearish | Sep 12, 2025 | 1 year ago |
| SMA: Bullish | Sep 11, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Sep 10, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 26, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 15, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 6, 2025 | 1 year ago |
| RSI: Overbought | Jul 23, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 9, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 20, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 4, 2025 | 1 year ago |
| SMA: Bearish | May 30, 2025 | 1 year ago |
| SMA: Bullish | May 29, 2025 | 1 year ago |
| SMA: Bearish | May 15, 2025 | 1 year ago |
| MACD: Sell Signal | May 6, 2025 | 1 year ago |
| SMA: Bullish | Apr 17, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| MACD: Sell Signal | Apr 9, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 27, 2025 | 1 year ago |
| RSI: Oversold | Mar 25, 2025 | 1 year ago |
| RSI: Oversold | Mar 20, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 18, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 10, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 21, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 19, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 7, 2025 | 1 year ago |
| MACD: Buy Signal | Feb 6, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 3, 2025 | 1 year ago |
| MACD: Buy Signal | Dec 23, 2024 | 1 year ago |
Key statistics
- Market cap
- 176.42M
- Enterprise value
- -30.36M
- Trailing P/E
- 0.00
- Forward P/E
- -1.42
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.41
- EPS (TTM)
- -1.83
- Beta
- 0.87
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -69.58M
- Total cash
- 283.06M
- Total debt
- 85.45M
- Return on equity
- -30.40%
- Shares outstanding
- 70.57M
- Short % of float
- 12.49%
- 50-day average
- 3.03
- 200-day average
- 5.86
Analyst view
Consensus: none
Price target (mean) 15.83 +915.0% upside
Now 1.56
- Target (low)
- 11.00
- Target (mean)
- 15.83
- Target (high)
- 20.00
Ratings (0m) 8 8 buy · 0 hold · 0 sell
- Strong buy2
- Buy6
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate -0.40.
Financials — quick view
NKTX Revenue — quarterly 0
NKTX Net income — quarterly -40.37M
NKTX EPS — quarterly -0.54
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.37 | -0.39 | -0.02 | -5.41% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | -0.34 | +0.15 | +30.61% |
| Aug 13, 2024 | Jun 1, 2024 | -0.49 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.56 | -0.58 | -0.02 | -3.57% |
| May 9, 2024 | Mar 1, 2024 | -0.56 | — | — | — |
| Mar 21, 2024 | Dec 1, 2023 | -0.62 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 21, 2024 | Mizuho | main | Outperform | Outperform |
| Nov 11, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 8, 2024 | Needham | main | Buy | Buy |
| Aug 15, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Aug 14, 2024 | Needham | reit | Buy | Buy |
| Aug 14, 2024 | Raymond James | up | Outperform | Strong Buy |
About Nkarta, Inc.
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- nkartatx.com
News
- Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
- Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
- Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
- Nkarta to Participate in September Investor Conferences
- Nkarta to Present Initial Autoimmune Clinical Data for NKX019 at American College of Rheumatology (ACR) Convergence 2026
- 6,300,212 Shares in Nkarta, Inc. $NKTX Acquired by BlackRock Inc.
- Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development
- Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- The $13 Million Company Teaching the Immune System to Hunt Cancer
- Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
Your note
Sign in to keep a note on NKTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BRANDENBERGER RALPH ERIK | Chief Technology Officer | Sale | Jun 17, 2024 | 79,743 |
| GEORGE SIMEON J. | Director | Purchase | Mar 26, 2024 | 0 |
| HAGER ALICIA J | Officer | Sale | Jul 15, 2024 | 103,819 |
| HASTINGS PAUL J | Chief Executive Officer | Sale | Jun 17, 2024 | 240,737 |
| LEVIN ALYSSA | Chief Financial Officer | Stock Award(Grant) | Jan 3, 2024 | 56,000 |
| MAHMOOD NADIR AHMEDUDDIN | Chief Financial Officer | Sale | Jun 19, 2023 | 85,776 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| RA Capital Management, L.P. | 15.31% | 10,805,129 | 27.01M | Sep 29, 2024 |
| Commodore Capital Lp | 6.61% | 4,662,073 | 11.66M | Sep 29, 2024 |
| Blackrock Inc. | 5.98% | 4,222,380 | 10.56M | Sep 29, 2024 |
| Boxer Capital, LLC | 5.71% | 4,029,606 | 10.07M | Sep 29, 2024 |
| Samsara BioCapital, LLC | 5.34% | 3,768,035 | 9.42M | Sep 29, 2024 |
| Adage Capital Partners GP L.L.C. | 5.10% | 3,600,000 | 9.00M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.58% | 1,818,558 | 4.55M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 1.95% | 1,373,111 | 3.43M | Oct 30, 2024 |
| Wasatch Ultra Growth Fund | 1.45% | 1,024,570 | 2.56M | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 1.00% | 704,875 | 1.76M | Sep 29, 2024 |
| Wasatch Microcap Fund | 0.95% | 668,362 | 1.67M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.77% | 542,221 | 1.36M | Aug 30, 2024 |